Conjunctivitis
4
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
On Market (2)
Approved therapies currently available
U
LOTEPREDNOL ETABONATE AND TOBRAMYCINApproved
loteprednol etabonate and tobramycin
Unknown CompanyAminoglycoside Antibacterial [EPC]ophthalmic2025
ZYLETApproved
loteprednol etabonate and tobramycin
Bausch + LombAminoglycoside Antibacterial [EPC]ophthalmic2004
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Bausch + LombNJ - Bridgewater
2 programs1
1
loteprednol etabonate and tobramycinPhase 41 trial
Loteprednol and tobramycinPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bausch + Lombloteprednol etabonate and tobramycin
Bausch + LombLoteprednol and tobramycin
Clinical Trials (2)
Total enrollment: 494 patients across 2 trials
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Start: Jun 2008Est. completion: May 2010137 patients
Phase 4Completed
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Start: Oct 2009Est. completion: Mar 2010357 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space